By Week @ , more mavrilimumab - versus placebo-treated subjects achieved a DAS@-CRP response ( @ % vs. @ % , p = @ ) ; a significant response was seen in the @ mg and @ mg dose groups ( both @ % vs. @ % , p = @ ) .